Mantle cell lymphoma (MCL) is a rare, aggressive Non-Hodgkin lymphoma that remains incurable despite recent prognostic improvements.1,2 The role of Bruton’s tyrosine kinase (BTK) inhibitors in treating MCL will evolve substantially over the coming years as results from a number of clinical trials become available.1 This webinar will provide an overview of MCL, current unmet treatment needs, and the role of a second-generation BTK inhibitor in MCL treatment.

This webinar is sponsored, developed and presented by BieGene. Click on the link below to access the webinar.


Michael Kolodziej MD, FACP
VP and Chief Innovation Officer

References: 1. Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233-e240. 2. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710-725.